EP4705316A2 - Anticorps ciblant un complexe peptidique de cathepsine g d'antigène leucocytaire humain - Google Patents

Anticorps ciblant un complexe peptidique de cathepsine g d'antigène leucocytaire humain

Info

Publication number
EP4705316A2
EP4705316A2 EP24800677.7A EP24800677A EP4705316A2 EP 4705316 A2 EP4705316 A2 EP 4705316A2 EP 24800677 A EP24800677 A EP 24800677A EP 4705316 A2 EP4705316 A2 EP 4705316A2
Authority
EP
European Patent Office
Prior art keywords
antibody
antigen binding
seq
antibodies
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24800677.7A
Other languages
German (de)
English (en)
Inventor
Jeffrey J. Molldrem
Dongxing Zha
Melinda G. Smith
Gheath AL-ATRASH
Jason K. Allen
Chunhua Shi
Ze TIAN
Timothy E. Lofton
Jun Yan
Jasbir KAUR
Bhupal BAN
Alona KULESHA
Nga Sze Amanda MAK
Melissa Jennifer BIKOWITZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of EP4705316A2 publication Critical patent/EP4705316A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4247—Proteinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Sont proposés des anticorps ou des parties de liaison aux antigènes de ceux-ci qui se lient spécifiquement à des antigènes se rapportant à des malignités myéloïdes, diverses compositions de tels anticorps ou parties de liaison aux antigènes de ceux-ci, et des procédés d'utilisation de ceux-ci. La divulgation concerne de tels anticorps, des fragments de tels anticorps conservant la capacité de liaison aux antigènes de malignité myéloïde, des compositions pharmaceutiques comprenant de tels anticorps ou leurs fragments de liaison aux antigènes, et des compositions de diagnostic comprenant de tels anticorps ou leurs fragments de liaison aux antigènes. La divulgation concerne également des acides nucléiques isolés codant pour de telles séquences d'acides aminés d'anticorps de tels anticorps et des cellules hôtes transformées par ces dernières. En outre, la présente divulgation concerne des procédés thérapeutiques et diagnostiques utilisant les anticorps et les acides nucléiques selon la divulgation. Enfin, la présente divulgation concerne des anticorps bispécifiques recombinants capables de se lier spécifiquement à CG1 et CD3.
EP24800677.7A 2023-05-03 2024-05-03 Anticorps ciblant un complexe peptidique de cathepsine g d'antigène leucocytaire humain Pending EP4705316A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363499881P 2023-05-03 2023-05-03
US202463640098P 2024-04-29 2024-04-29
PCT/US2024/027704 WO2024229369A2 (fr) 2023-05-03 2024-05-03 Anticorps ciblant un complexe peptidique de cathepsine g d'antigène leucocytaire humain

Publications (1)

Publication Number Publication Date
EP4705316A2 true EP4705316A2 (fr) 2026-03-11

Family

ID=93333384

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24800677.7A Pending EP4705316A2 (fr) 2023-05-03 2024-05-03 Anticorps ciblant un complexe peptidique de cathepsine g d'antigène leucocytaire humain

Country Status (7)

Country Link
EP (1) EP4705316A2 (fr)
KR (1) KR20260020503A (fr)
CN (1) CN121399146A (fr)
AU (1) AU2024264872A1 (fr)
IL (1) IL324392A (fr)
MX (1) MX2025013106A (fr)
WO (1) WO2024229369A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053304B1 (en) * 2020-03-23 2021-07-06 Centivax, Inc. Anti-SARS-Cov-2 antibodies derived from 6nb6
WO2022241200A1 (fr) * 2021-05-14 2022-11-17 Vanderbilt University Anticorps anti-coronavirus à réactivité croisée

Also Published As

Publication number Publication date
CN121399146A (zh) 2026-01-23
WO2024229369A3 (fr) 2025-02-13
IL324392A (en) 2026-01-01
AU2024264872A1 (en) 2025-11-27
WO2024229369A2 (fr) 2024-11-07
KR20260020503A (ko) 2026-02-11
MX2025013106A (es) 2026-02-03
WO2024229369A9 (fr) 2025-08-07

Similar Documents

Publication Publication Date Title
EP3126388B1 (fr) Anticorps anti-egfrviii et utilisations associées
JP2024012313A (ja) 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
US20240376224A1 (en) Antibodies against cleaved cdcp1 and uses thereof
US12098178B2 (en) Methods of using interleukin-2 agents
US20240209094A1 (en) New stable anti-vista antibody
WO2024102980A1 (fr) Anticorps anti-intégrine alpha5 et leurs utilisations
EP4705316A2 (fr) Anticorps ciblant un complexe peptidique de cathepsine g d'antigène leucocytaire humain
KR20240024061A (ko) 항-EGFRvIII 항체 약물 접합체 및 이의 용도
US20250222105A1 (en) Anti-rori antibody and chimeric antigen receptor and methods of use thereof
US20250018037A1 (en) Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
WO2026037330A1 (fr) Anticorps se liant à cd3 et leurs utilisations
WO2024163499A1 (fr) Anticorps à sélectivité pour l'isoforme 4ig de b7-h3 et leurs méthodes d'utilisation
WO2026036085A1 (fr) Anticorps ciblant le ddl3 et leurs procédés d'utilisation
WO2025106118A2 (fr) Anticorps anti-cd138/syndécan1 et procédés d'utilisation associés
WO2025230866A1 (fr) Anticorps anti-intégrine alpha5 et leurs utilisations
HK1232899B (en) Anti-egfrviii antibodies and uses thereof
HK1232899A1 (en) Anti-egfrviii antibodies and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR